Fairman Jeff
VP, Research at PCVX
- Sold, on record
- $2.9M
- Dollars the filings state
- Form 4 sales
- 20
- Latest Oct 26, 2022
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- PCVXVaxcyte, Inc.VP, Research
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale PCVXPlan not statedMar 11, 2022 2022
Sold 10,000 shares at $25.50 ($255k)
Fairman Jeff, VP, Research
Sold 2.9% of holdings ($8.7M position)331,227 shares left2.1x usual sizeFiling
- 2 Form 4 sale PCVXPlan not statedApr 5, 2022 +25 days
Sold 5,000 shares at $25.59 ($128k)
Fairman Jeff, VP, Research
Sold 1.5% of holdings ($8.5M position)326,227 shares left1.1x usual sizeFiling
- 3 Form 4 sale PCVXPlan not statedMay 5, 2022 +30 days
Sold 888 shares at $25.80 ($23k)
Fairman Jeff, VP, Research
Sold 0.3% of holdings ($8.4M position)325,339 shares left0.2x usual sizeFiling
- 4 Form 4 sale PCVXPlan not statedMay 20, 2022 +15 days
Sold 4,112 shares at $25.50 ($105k)
Fairman Jeff, VP, Research
Sold 1.3% of holdings ($8.3M position)321,227 shares left0.9x usual sizeFiling
- 5 Form 4 sale PCVXUnusualAug 5, 2022 +77 days
Sold 15,000 shares at $25.57 ($384k)
Fairman Jeff, VP, Research
Sold 4.7% of holdings ($8.2M position)306,227 shares left3.2x usual sizeFiling
- 6 Form 4 sale PCVXPlan not statedSep 6, 2022 +32 days
Sold 5,000 shares at $26.58 ($133k)
Fairman Jeff, VP, Research
Sold 1.6% of holdings ($8.1M position)301,227 shares left1.1x usual sizeFiling
- 7 Form 4 sale PCVXPlan not statedOct 11, 2022 +35 days
Sold 5,000 shares at $25.50 ($128k)
Fairman Jeff, VP, Research
Sold 1.7% of holdings ($7.7M position)296,227 shares left1.1x usual sizeFiling
- 8 Form 4 sale PCVXPlan not statedOct 26, 2022 +15 days
Sold 10,000 shares at $40.00 ($400k)
Fairman Jeff, VP, Research
Sold 3.4% of holdings ($11.8M position)286,227 shares left2.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (20)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 2022 | Oct 28, 2022 | PCVX | VP, Research | Form 4 sale | 10,000 | $400k | 3.4% | Plan not stated | SEC |
| Oct 11, 2022 | Oct 13, 2022 | PCVX | VP, Research | Form 4 sale | 5,000 | $128k | 1.7% | Plan not stated | SEC |
| Sep 6, 2022 | Sep 7, 2022 | PCVX | VP, Research | Form 4 sale | 5,000 | $133k | 1.6% | Plan not stated | SEC |
| Aug 5, 2022 | Aug 5, 2022 | PCVX | VP, Research | Form 4 sale | 15,000 | $384k | 4.7% | Unusual | SEC |
| May 20, 2022 | May 24, 2022 | PCVX | VP, Research | Form 4 sale | 4,112 | $105k | 1.3% | Plan not stated | SEC |
| May 5, 2022 | May 9, 2022 | PCVX | VP, Research | Form 4 sale | 888 | $23k | 0.3% | Plan not stated | SEC |
| Apr 5, 2022 | Apr 7, 2022 | PCVX | VP, Research | Form 4 sale | 5,000 | $128k | 1.5% | Plan not stated | SEC |
| Mar 11, 2022 | Mar 15, 2022 | PCVX | VP, Research | Form 4 sale | 10,000 | $255k | 2.9% | Plan not stated | SEC |
| Dec 27, 2021 | Dec 28, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $112k | 43.5% | Unusual | SEC |
| Dec 16, 2021 | Dec 20, 2021 | PCVX | VP, Research | Form 4 sale | 4,619 | $104k | 42.9% | Unusual | SEC |
| Dec 9, 2021 | Dec 13, 2021 | PCVX | VP, Research | Form 4 sale | 131 | $3k | 2.1% | Plan not stated | SEC |
| Oct 26, 2021 | Oct 28, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $108k | 48.0% | Unusual | SEC |
| Sep 27, 2021 | Sep 29, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $124k | 48.0% | Unusual | SEC |
| Aug 26, 2021 | Aug 30, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $121k | 48.0% | Unusual | SEC |
| Jul 26, 2021 | Jul 28, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $108k | 48.0% | Unusual | SEC |
| Jun 28, 2021 | Jun 30, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $116k | 48.0% | Unusual | SEC |
| Jun 7, 2021 | Jun 9, 2021 | PCVX | VP, Research | Form 4 sale | 9,500 | $214k | 64.9% | Unusual | SEC |
| Mar 26, 2021 | Mar 29, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $113k | 77.1% | Unusual | SEC |
| Feb 26, 2021 | Mar 2, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $114k | 77.1% | Unusual | SEC |
| Jan 26, 2021 | Jan 28, 2021 | PCVX | VP, Research | Form 4 sale | 4,750 | $120k | 77.1% | Unusual | SEC |